Download Japan Tobacco Pharma

Japan Tobacco Pharma
DELEGATE(S)
Yuji Kando
Shuichi Kotaka, Manager, Pharmaceutical Business Development
2-2-1, Toranomon, Minato-ku
Tokyo 105-8422
Japan
www.jt.com
Incorporated: 1985
Employees:
7100
Ownership:
Public
Tokyo Stock Exchange: 2914
MISSION/BACKGROUND
The Pharmaceutical Division of Japan Tobacco is a fully-integrated pharmaceutical entity
dedicated to the discovery, development and marketing of novel human therapeutics. Our
focus is on the identification of small molecule, orally available drugs to treat a variety of
diseases, including: metabolic diseases (diabetes, obesity, dyslipidemia, osteoporosis, etc.);
autoimmune/inflammatory diseases; and certain viral diseases (HIV infection and
hepatitis C). Our sales franchises include products sold by our marketing subsidiary Torii
Pharmaceutical for: renal diseases (hemodialysis patients) and urology; dermatology;
infectious diseases (such as HIV); surgery and intensive care; and gastrointestinal diseases.
JT seeks partnering opportunities to facilitate new drug discovery and development, such as products in early-stage development, new
lead compounds, new drug targets, in vivo and in vitro assays, compound libraries, etc. JT also seeks products in late-stage
development for Japanese market to be launched by Torii.
TECHNOLOGY
JT is highly oriented to R&D on its own, and has all the capabilities and technologies necessary for small moleule drug discovery and
development. JT's preclinical R&D work is performed at its Central Pharmaceutical Research Institute, of which main facility is located
near Osaka. Akros Pharma, which is a wholly-owned subsidiary of JT located in Princeton, New Jersey, conducts clinical development of
JT compounds in the U.S. and Europe. Torii Pharmaceutical, one of the oldest pharmaceutical companies in Japan, is engaged in sales
and marketing of products developed by JT inside the country as mentioned above.
ALLIANCES
JT has successfully established a number of strategic alliances, including product and technology licensing arrangements, research
collaborations, funding and joint ventures with several pharmaceutical and biotech companies outside of Japan including: Gilead,
Keryx, Roche, MedImmune, and GlaxoSmithKline.
Company Profiles – 50